Unveiling the Potential of the Ta:RNATM platform

The Ta:RNA™ platform targets solid tumors through over-expression of a specific receptor. The power of Ta:RNA™ is driven by targeted apoptosis and tumor-specific immune response, independent of receptor activity.

Our development programme has initially focused on three key receptor targets representing 10,000s of potential patients each year.

TAR001 has been chosen as the lead compound and is currently approaching Phase 1 clinical trials.